{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:59:25Z","timestamp":1771671565456,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40264-025-01613-x","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T08:12:30Z","timestamp":1759133550000},"page":"313-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Choosing an Index Date for Untreated Patients in External Comparator Studies"],"prefix":"10.1007","volume":"49","author":[{"given":"Luis","family":"Antunes","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-8465","authenticated-orcid":false,"given":"Gerd","family":"Rippin","sequence":"additional","affiliation":[]},{"given":"Eleanor","family":"Ralphs","sequence":"additional","affiliation":[]},{"given":"Artis","family":"Luguzis","sequence":"additional","affiliation":[]},{"given":"Kellyn","family":"Arnold","sequence":"additional","affiliation":[]},{"given":"Hopin","family":"Lee","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"8","key":"1613_CR1","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jval.2021.01.015","volume":"24","author":"D Patel","year":"2021","unstructured":"Patel D, Grimson F, Mihaylova E, et al. Use of external comparators for health technology assessment submissions based on single-arm trials. Value Health. 2021;24(8):1118\u201325. https:\/\/doi.org\/10.1016\/j.jval.2021.01.015.","journal-title":"Value Health"},{"issue":"8","key":"1613_CR2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40264-022-01206-y","volume":"45","author":"G Rippin","year":"2022","unstructured":"Rippin G, Ballarini N, Sanz H, Largent J, Quinten C, Pignatti F. A review of causal inference for external comparator arm studies. Drug Saf. 2022;45(8):815\u201337. https:\/\/doi.org\/10.1007\/s40264-022-01206-y.","journal-title":"Drug Saf"},{"issue":"1","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-020-1332-x","volume":"15","author":"M Ghadessi","year":"2020","unstructured":"Ghadessi M, Tang R, Zhou J, et al. A roadmap to using historical controls in clinical trials\u2014by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet J Rare Dis. 2020;15(1):1\u201319. https:\/\/doi.org\/10.1186\/s13023-020-1332-x.","journal-title":"Orphanet J Rare Dis"},{"key":"1613_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2120","author":"HU Burger","year":"2021","unstructured":"Burger HU, Gerlinger C, Harbron C, et al. The use of external controls: To what extent can it currently be recommended? Pharma Stat. 2021. https:\/\/doi.org\/10.1002\/pst.2120.","journal-title":"Pharma Stat"},{"key":"1613_CR5","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/pds.5141","volume":"29","author":"JD Seeger","year":"2020","unstructured":"Seeger JD, Davis KJ, Innacone MR, et al. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. Pharmacoepidemiology. 2020;29:1382\u201392. https:\/\/doi.org\/10.1002\/pds.5141.","journal-title":"Pharmacoepidemiology"},{"key":"1613_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2018.06.036","volume":"101","author":"E Skovlund","year":"2018","unstructured":"Skovlund E, Leufkens HGM, Smyth JF. The use of real-world data in cancer drug development. Eur J Cancer. 2018;101:69\u201376. https:\/\/doi.org\/10.1016\/j.ejca.2018.06.036.","journal-title":"Eur J Cancer"},{"key":"1613_CR7","doi-asserted-by":"publisher","first-page":"1321894","DOI":"10.3389\/fdsfr.2023.1321894","volume":"3","author":"G Rippin","year":"2024","unstructured":"Rippin G, Largent J, Hoogendoorn WE, Sanz H, Bosco J, Mack C. External comparator cohort studies\u2014clarification of terminology. Front Drug Saf Regul. 2024;3:1321894. https:\/\/doi.org\/10.3389\/fdsfr.2023.1321894.","journal-title":"Front Drug Saf Regul."},{"key":"1613_CR8","doi-asserted-by":"publisher","first-page":"1332040","DOI":"10.3389\/fdsfr.2023.1332040","volume":"3","author":"G Rippin","year":"2024","unstructured":"Rippin G. External comparators and estimands. Front Drug Saf Regul. 2024;3:1332040. https:\/\/doi.org\/10.3389\/fdsfr.2023.1332040.","journal-title":"Front Drug Saf Regul."},{"key":"1613_CR9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40264-024-01467-9","volume":"47","author":"G Rippin","year":"2024","unstructured":"Rippin G, Sanz H, Hoogendoorn WE, et al. Examining the effect of missing data and unmeasured confounding on external comparator studies: case studies and simulations. Drug Saf. 2024;47:1245\u201363. https:\/\/doi.org\/10.1007\/s40264-024-01467-9.","journal-title":"Drug Saf"},{"key":"1613_CR10","doi-asserted-by":"publisher","first-page":"1409102","DOI":"10.3389\/fdsfr.2024.1409102","volume":"4","author":"G Rippin","year":"2024","unstructured":"Rippin G, Sanz H. External comparator studies and the joint application of the estimand frameworks. Front Drug Saf Regul. 2024;4:1409102. https:\/\/doi.org\/10.3389\/fdsfr.2024.1409102.","journal-title":"Front Drug Saf Regul"},{"issue":"4","key":"1613_CR11","doi-asserted-by":"publisher","first-page":"1380568","DOI":"10.3389\/fdsfr.2024.1380568","volume":"2024","author":"K Arnold","year":"2024","unstructured":"Arnold K, Antunes L, Coles B, Lee H. Application of the target trial emulation framework to external comparator studies. Front Drug Saf Regul. 2024;2024(4):1380568. https:\/\/doi.org\/10.3389\/fdsfr.2024.1380568.","journal-title":"Front Drug Saf Regul"},{"key":"1613_CR12","doi-asserted-by":"publisher","unstructured":"Rippin G, Sanz H, Hoogendoorn WE, Largent, JA. External comparator studies: performance of four missing data\u2011handling approaches, stratified by four different marginal estimators. Drug Saf. 2025;48. https:\/\/doi.org\/10.1007\/s40264-025-01586-x","DOI":"10.1007\/s40264-025-01586-x"},{"key":"1613_CR13","unstructured":"United States Food and Drug Administration (FDA). Considerations for the design and conduct of externally controlled trials for drug and biological products. Draft Guidance for Industry, 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products Accessed 30 June 2025."},{"key":"1613_CR14","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pst.2107","volume":"20","author":"D Backenroth","year":"2021","unstructured":"Backenroth D. How to choose a time zero for patients in external control arms. Pharm Stat. 2021;20:783\u201392. https:\/\/doi.org\/10.1002\/pst.2107.","journal-title":"Pharm Stat"},{"issue":"7","key":"1613_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1177\/0272989X221096070","volume":"42","author":"AJ Hatswell","year":"2022","unstructured":"Hatswell AJ, Deighton K, Snider JT, Brookhart MA, Faghmous I, Patel AR. Approaches to selecting \u2018\u201ctime zero\u201d\u2019 in external control arms with multiple potential entry points: a simulation study of 8 approaches. Med Decis Mak. 2022;42(7):893\u2013905. https:\/\/doi.org\/10.1177\/0272989X221096070.","journal-title":"Med Decis Mak"},{"issue":"1","key":"1613_CR16","doi-asserted-by":"publisher","first-page":"20230041","DOI":"10.1515\/em-2023-0041","volume":"13","author":"H Van Le","year":"2024","unstructured":"Van Le H, De Benedetti M, Yue L, Fang L, Van Naarden BK, Lin PC, et al. Effect of designations of index date in externally controlled trials: an empirical example. Epidemiol Methods. 2024;13(1):20230041. https:\/\/doi.org\/10.1515\/em-2023-0041.","journal-title":"Epidemiol Methods"},{"issue":"6","key":"1613_CR17","doi-asserted-by":"publisher","first-page":"S280","DOI":"10.1016\/j.jval.2024.03.2420","volume":"27","author":"Z Cui","year":"2024","unstructured":"Cui Z, Khanal M, Chen Y, Li X, Winfree K. MSR105 proportional randomization method to identify index line of therapy in externally controlled trials. Value Health. 2024;27(6):S280. https:\/\/doi.org\/10.1016\/j.jval.2024.03.2420.","journal-title":"Value Health"},{"key":"1613_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40801-022-00343-1","volume":"10","author":"R Wakabayashi","year":"2023","unstructured":"Wakabayashi R, Hirano T, Laurent T, Kuwatsuru Y, Kuwatsuru R. Impact of \u201ctime zero\u201d of follow-up settings in a comparative effectiveness study using real-world data with a non-user comparator: comparison of six different settings. Drugs Real World Outcomes. 2023;10:107\u201317. https:\/\/doi.org\/10.1007\/s40801-022-00343-1.","journal-title":"Drugs Real World Outcomes"},{"key":"1613_CR19","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/aje\/kwi307","volume":"162","author":"Z Zhou","year":"2005","unstructured":"Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol. 2005;162:1016\u201323. https:\/\/doi.org\/10.1093\/aje\/kwi307.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"1613_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/aje\/kwv445","volume":"184","author":"ME Karim","year":"2016","unstructured":"Karim ME, Gustafson P, Petkau J, Tremlett H, the Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol. 2016;184(4):325\u201335. https:\/\/doi.org\/10.1093\/aje\/kwv445.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/aje\/kww156","volume":"184","author":"M Wolkewitz","year":"2016","unstructured":"Wolkewitz M, Beyersmann J, Ohneberg K, Schumacher M. Letter to the editor regarding \u2018Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies.\u2019 Am J Epidemiol. 2016;184(11):856\u201385. https:\/\/doi.org\/10.1093\/aje\/kww156.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"1613_CR22","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/aje\/kww158","volume":"184","author":"ME Karim","year":"2016","unstructured":"Karim ME, Gustafson P, Petkau J, Tremlett H, the Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group. Rejoinder for \u2018Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies.\u2019 Am J Epidemiol. 2016;184(11):856\u20138. https:\/\/doi.org\/10.1093\/aje\/kww158.","journal-title":"Am J Epidemiol"},{"key":"1613_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3414\/ME9241","volume":"48","author":"M Wolkewitz","year":"2009","unstructured":"Wolkewitz M, Beyersmann J, Gastmeier P, et al. Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inf Med. 2009;48:438\u201343. https:\/\/doi.org\/10.3414\/ME9241.","journal-title":"Methods Inf Med"},{"key":"1613_CR24","doi-asserted-by":"publisher","unstructured":"Wang J, Peduzzi P, Wininger M, Ma S. Statistical methods for accommodating immortal time: a selective review and comparison. In: Biostatistics in biopharmaceutical research and development: clinical trial analysis, vol 2. Springer Nature, Switzerland; 2024. p. 53\u201392. https:\/\/doi.org\/10.1007\/978-3-031-65937-9_3.","DOI":"10.1007\/978-3-031-65937-9_3"},{"issue":"1","key":"1613_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14376","volume":"60","author":"D Weymann","year":"2025","unstructured":"Weymann D, Krebs E, Regier DA. Addressing immortal time bias in precision medicine: practical guidance and methods development. Health Serv Res. 2025;60(1):e14376. https:\/\/doi.org\/10.1111\/1475-6773.14376.","journal-title":"Health Serv Res"},{"issue":"20","key":"1613_CR26","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378(20):1898\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa1712649.","journal-title":"N Engl J Med"},{"key":"1613_CR27","unstructured":"European Medicines Agency (EMA) Zolgensma European Assessment Report, EMA\/200482\/2020, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zolgensma-epar-public-assessment-report_en.pdf. Accessed 03 July 2025."},{"issue":"8","key":"1613_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"key":"1613_CR29","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/add.16473","volume":"119","author":"PJ Christine","year":"2024","unstructured":"Christine PJ, Lodi S, Hsu HE, et al. Target trial emulation for comparative effectiveness research with observational data: promise and challenges for studying medications for opioid use disorder. Addiction. 2024;119:1313\u201321. https:\/\/doi.org\/10.1111\/add.16473.","journal-title":"Addiction"},{"issue":"6","key":"1613_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/pst.2127","volume":"20","author":"Q Xu","year":"2021","unstructured":"Xu Q, Przepiorka D. Using marginal structural models to analyze the impact of subsequent therapy on the treatment effect in survival data: simulations and clinical trial examples. Pharm Stat. 2021;20(6):1088\u2013101. https:\/\/doi.org\/10.1002\/pst.2127.","journal-title":"Pharm Stat"},{"key":"1613_CR31","doi-asserted-by":"publisher","first-page":"ii84","DOI":"10.1093\/ndt\/gfw341","volume":"32","author":"T Williamson","year":"2017","unstructured":"Williamson T, Ravani P. Marginal structural models in clinical research: when and how to use them? Nephrol Dial Transpl. 2017;32:ii84\u201390. https:\/\/doi.org\/10.1093\/ndt\/gfw341.","journal-title":"Nephrol Dial Transpl"},{"key":"1613_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/2167696815621645","volume":"4","author":"F Thoemmes","year":"2016","unstructured":"Thoemmes F, Ong AD. A primer on inverse probability of treatment weighting and marginal structural models. Emerg Adulthood. 2016;4:40\u201359. https:\/\/doi.org\/10.1177\/2167696815621645.","journal-title":"Emerg Adulthood"},{"key":"1613_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2188\/jea.JE20200226","volume":"30","author":"T Shinozaki","year":"2020","unstructured":"Shinozaki T, Suzuki E. Understanding marginal structural models for time-varying exposures: pitfalls and tips. J Epidemiol. 2020;30:377\u201389. https:\/\/doi.org\/10.2188\/jea.JE20200226.","journal-title":"J Epidemiol"},{"key":"1613_CR34","volume-title":"Real world health care data analysis: causal methods and implementation in SAS","author":"DE Faries","year":"2020","unstructured":"Faries DE, Zhang X, Kadziola Z, et al. Real world health care data analysis: causal methods and implementation in SAS. Cary: SAS Institute; 2020."},{"key":"1613_CR35","doi-asserted-by":"publisher","DOI":"10.1201\/9781315374932","volume-title":"Causal inference: what if","author":"MA Hern\u00e1n","year":"2023","unstructured":"Hern\u00e1n MA, Robins JM. Causal inference: what if. Boca Raton: Chapman & Hall\/CRC; 2023. https:\/\/doi.org\/10.1201\/9781315374932."},{"issue":"1","key":"1613_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ije\/dyy218","volume":"48","author":"PJ Clare","year":"2019","unstructured":"Clare PJ, Dobbins TA, Mattick RP. Causal models adjusting for time-varying confounding\u2014a systematic review of the literature. Int J Epidemiol. 2019;48(1):254\u201365. https:\/\/doi.org\/10.1093\/ije\/dyy218.","journal-title":"Int J Epidemiol"},{"issue":"9","key":"1613_CR37","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/sim.5686","volume":"32","author":"RM Daniel","year":"2013","unstructured":"Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA. Methods for dealing with time-dependent confounding. Stat Med. 2013;32(9):1584\u2013618. https:\/\/doi.org\/10.1002\/sim.5686.","journal-title":"Stat Med"},{"key":"1613_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5886","volume":"33","author":"G Rippin","year":"2024","unstructured":"Rippin G, Salmasi S, Sanz H, Largent J. Core concepts in pharmacoepidemiology: time-to-event analysis approaches in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2024;33:e5886. https:\/\/doi.org\/10.1002\/pds.5886.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1613_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/9781118762516","volume-title":"Clinical trials with missing data. A guide for practitioners","author":"M O\u2019Kelly","year":"2014","unstructured":"O\u2019Kelly M, Ratitch B. Clinical trials with missing data. A guide for practitioners. Chichester: Wiley; 2014. https:\/\/doi.org\/10.1002\/9781118762516."},{"issue":"5","key":"1613_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5796","volume":"33","author":"C Gray","year":"2024","unstructured":"Gray C, Ralphs E, Fox MP, Lash TL, Liu G, Kou TD, et al. Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls. Pharmacoepidemiol Drug Saf. 2024;33(5):e5796. https:\/\/doi.org\/10.1002\/pds.5796.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01613-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:00:14Z","timestamp":1771668014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01613-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01613-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected with author corrections.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interests that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participation"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No real patient data were used. Data as generated by simulation code are available in the Online Resource.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The programming code for the simulations is available in the Online Resource.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LA prepared the simulation programs and wrote the first draft of the manuscript. Further drafts until manuscript finalization were written by GR. AL performed additional programming work including quality control of the written simulation code. All co-authors reviewed and revised the manuscript and participated sufficiently in the work to take responsibility of portions of the content. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}